Differences In the Gene Expression Profile of Matrix Metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 67-74

  Gentner, Bernhard ^a,e   Wein, Axel ^a   Croner, Roland S ^a   Zeittraeger, Isabel ^a   Wirtz, Ralph M ^b   Roedel, Franz ^c   Dimmler, Arno ^d   Dorlaque, Laure ^a   Hohenberger, Werner ^a   Hahn, Eckhart G ^a   Brueckl, Wolfgang M ^a,f,g  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Siemens Medical Solutions GmbH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Karlsruhe City Hospital   (Germany)

^e SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

^g State Hospital Mittersill   (Austria)

Author keywords

Colorectal carcinoma (crc); Inhibitor of matrix metalloproteinase (timp); Matrix metalloproteinase (mmp); Microarray analysis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; OXALIPLATIN; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DNA MICROARRAY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 61449230902     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW: Colorectal cancer. Lancet 365: 153-165, 2005.
2. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
3. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J and Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25: 3387-3391, 2005.
4. Wagenaar-Miller RA, Gorden L and Matrisian LM: Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 23: 119-135, 2004.
5. Cox G and O'Byrne KJ: Matrix metalloproteinases and cancer. Anticancer Res 21: 4207-4219, 2001.
6. Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ishikawa T, Mitsuhashi M, Shimada H and Miyazaki K: Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 76: 812-816, 1998.
7. Masuda H and Aoki H: Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer. Dis Colon Rectum 42: 393-397, 1999.
8. Matsuyama Y, Takao S and Aikou T: Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 80: 105-110, 2002.
9. Shah V, Kumar S and Zirvi KA: Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase. In Vivo 8: 321-326, 1994.
10. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR and Hoffman RM: Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 15: 184-195, 1997.
11. Aparicio T, Kermorgant S, Dessirier V, Lewin MJ and Lehy T: Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 20: 1445-1451, 1999.
12. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L and Matsuno S: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252-1258, 1999.
13. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392, 2002.
14. Leeman MF, Curran S and Murray GI: New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201: 528-534, 2003.
15. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10: 8229-8234, 2004.
16. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O and Laato M: Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 121: 714-723, 2007.
17. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, Hardcastle JD, Hermanek P, Jass JR and Newland RC: Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 6: 325-344, 1991.
18. Albrecht H, Wein A, Wolff K, Brueckl V, Meier C, Ostermeier N, Maennlein G, Hahn EG, Reulbach U, Hohenberger W and Boxberger F: Palliative first-line treatment with weekly high-dose 5-fluorouracil and sodium folinic acid (A10-schedule) as 24 h-infusion plus bi-weekly oxaliplatin in patients with definitively non-resectable metastatic colorectal cancer following secondary metastastic resection: an interdisciplinary phase II trial. Proc ASCO 26: 15064, 2008.
19. WHO: World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, Geneva, Switzerland, p. 48: 1979.
20. Eberwine J: Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA. Biotechniques 20: 584-591, 1996.
21. Grau M, Sole X, Obrador A, Tarafa G, Vendrell E, Vails J, Moreno V, Peinado MA and Capella G: Validation of RNA arbitrarily primed PCR probes hybridized to glass cDNA microarrays: application to the analysis of limited samples. Clin Chem 51: 93-101, 2005.
22. Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G, Feifel G, Zeitz M and Stallmach A: Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 16: 133-140, 2001.
23. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Dano K and Nielsen BS: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4: 293-302, 2006.
24. Fabra A, Nakajima M, Bucana CD and Fidler IJ: Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 52: 101-110, 1992.
25. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 472: 822-826, 2001.
26. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V and Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506, 2002.
27. Zeng ZS and Guillem JG: Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. Br J Cancer 78: 349-353, 1998.
28. Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190-196, 1996.
29. Hanke B, Wein A, Martus P, Riedel C, Voelker M, Hahn EG and Schuppan D: Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer 88: 1248-1250, 2003.
30. Rauvala M, Turpeenniemi-Hujanen T and Puistola U: The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer. Anticancer Res 26: 4779-4784, 2006.
31. Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, Topolcan O, Cerny R and Holubec L Jr: Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA in tissue samples from colorectal liver metastases. Tumour Biol 28: 247-252, 2007.
32. Ogawa M, Ikeuchi K, Watanabe M, Etoh K, Kobayashi T, Takao Y, Anazawa S and Yamazaki Y: Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach. Hepatogastroenterology 52: 875-880, 2005.
33. Bandres E, Zarate R, Ramirez N, Abajo A, Bitarte N and Gariia-Foncillas J: Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. World J Gastroenterol 13: 5888-5901, 2007.